Welcome to our dedicated page for Oruka Therapeutics news (Ticker: ORKA), a resource for investors and traders seeking the latest updates and insights on Oruka Therapeutics stock.
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases, and its news flow reflects the progress of a focused dermatology pipeline. Company press releases highlight advances for its lead monoclonal antibodies ORKA-001 and ORKA-002, both engineered to target key immunology pathways in plaque psoriasis and related conditions while enabling infrequent dosing.
News updates frequently cover clinical milestones such as Phase 1 interim data, initiation and enrollment of Phase 2 trials, and detailed designs of the EVERLAST-A and EVERLAST-B studies of ORKA-001 in moderate-to-severe plaque psoriasis. Oruka also reports on the first-in-human trial of ORKA-002, including pharmacokinetic and pharmacodynamic findings that support potential twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa.
In addition to pipeline developments, Oruka’s news includes quarterly financial results, corporate updates, and capital-raising activities, such as a private placement financing described in company communications. Governance and leadership items, including board appointments and executive promotions, are disclosed through both press releases and Form 8-K filings. The company also announces participation in major healthcare and investor conferences, where it presents clinical data and corporate overviews.
Investors and observers following ORKA news can expect coverage of clinical trial data readouts, regulatory milestones such as IND clearance, financing transactions, and changes in leadership or board composition. This page aggregates those updates so readers can monitor how Oruka’s psoriatic disease programs and broader antibody portfolio evolve over time.
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its upcoming participation at Piper Sandler's 36th Annual Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, December 3rd, 2024, at 3:00 PM ET.
Oruka Therapeutics (Nasdaq: ORKA) reported Q3 2024 financial results and corporate updates. The company raised over $475 million through two transactions and completed its public listing on Nasdaq. Key highlights include accelerated clinical timelines for ORKA-001 and ORKA-002, with Phase 1 trials planned for Q1 2025 and Q3 2025 respectively. Financial results show $410.9 million in cash and equivalents, with a net loss of $28.6 million. R&D expenses totaled $25.7 million, while G&A expenses were $3.8 million. The company expects its current cash position to provide runway through 2027.
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in two major investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference on November 18th at 2:25PM ET and the Jefferies London Healthcare Conference on November 20th at 2:00PM GMT. Webcasts and replays of the presentations will be accessible through Oruka's investor events website.
Oruka Therapeutics (Nasdaq: ORKA) announced preclinical data for ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the European Academy of Dermatology and Venereology Congress. Key findings include:
1. Non-human primate (NHP) half-life of 30.3 days (subcutaneous) and 33.8 days (intravenous), over three times longer than risankizumab.
2. Projected human half-life of ~50 days could enable dosing every six months; ~75 days could allow yearly dosing.
3. Binds to a similar epitope with comparable affinity to risankizumab (below 5 picomolar).
4. Equivalent potency across various in vitro assays.
The extended half-life could result in higher antibody exposures, potentially leading to greater efficacy in treating chronic skin diseases like plaque psoriasis.
Oruka Therapeutics (Nasdaq: ORKA) has announced a $200 million private placement financing. The biotechnology company, focused on developing novel biologics for chronic skin diseases, is selling 5,600,000 shares of common stock at $23.00 per share, 2,439 shares of Series A non-voting convertible preferred stock at $23,000 per share, and pre-funded warrants for 680,000 shares at $22.999 per warrant. The PIPE financing includes participation from both new and existing investors, including major investment firms. Upon closing, Oruka will have approximately 55.1 million shares of common stock and equivalents outstanding. The company plans to use the proceeds for research and development, general corporate expenses, and working capital, expecting to fund its operating plan through 2027.
Oruka Therapeutics (Nasdaq: ORKA) has announced accelerated timelines for its novel biologics targeting chronic skin diseases. ORKA-001, a half-life extended antibody targeting IL-23p19, is now expected to start first-in-human dosing in Q1 2025. ORKA-002, targeting IL-17A/F, is set for first-in-human dosing in Q3 2025.
ORKA-001 shows potential for once or twice yearly dosing, with higher exposures than current IL-23p19 antibodies, potentially leading to higher disease clearance rates. Preclinical data, including a half-life of over 30 days in non-human primates, will be presented at the European Academy of Dermatology and Venereology Congress (EADV) in September.
Interim data for ORKA-001 in healthy volunteers is expected in H2 2025, with initial efficacy data in psoriasis patients in H2 2026. For ORKA-002, interim data from healthy volunteers is anticipated in H1 2026.
Oruka Therapeutics, Inc. (Nasdaq: ORKA) has completed its merger with ARCA biopharma and a $275 million private placement. The company, focused on developing novel biologics for chronic skin diseases, begins trading on Nasdaq on September 3, 2024. Samarth Kulkarni, PhD, has been appointed as Chairman of Oruka's Board of Directors.
Oruka's pipeline includes two lead programs: ORKA-001, a subcutaneous IL-23p19 inhibitor potentially dosed once or twice yearly, and ORKA-002, a subcutaneous IL-17A/F inhibitor. Both aim to offer improved dosing regimens and greater clinical activity for psoriasis and related conditions. The company plans to advance these programs into clinical trials, with initial pharmacokinetic data for ORKA-001 expected next year.